BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10622045)

  • 41. [Therapeutic strategies for HIV infection: redefining simplification].
    Raffi F
    Med Mal Infect; 2004 Nov; 34 Suppl 3():S223-8. PubMed ID: 15906446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens.
    Visnegarwala F; Darcourt J; Sajja P; Menon V; Ong O; Maldonado M; White AC
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):653-5. PubMed ID: 12902814
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost effectiveness of combination HIV therapy: 3 years later.
    Moore RD
    Pharmacoeconomics; 2000 Apr; 17(4):325-30. PubMed ID: 10947487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. What dual protease inhibitor combination for salvage therapies?
    Rodríguez-Rosado R; Soriano V; Barreiro P; Dona C; González-Lahoz J
    AIDS; 1999 Oct; 13(15):2180-1. PubMed ID: 10546879
    [No Abstract]   [Full Text] [Related]  

  • 45. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.
    Fisher SD; Miller TL; Lipshultz SE
    Atherosclerosis; 2006 Mar; 185(1):1-11. PubMed ID: 16297390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing and enhancing compliance with antiretroviral therapy.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1997 Apr; 22(4):211-2, 215, 219. PubMed ID: 9128888
    [No Abstract]   [Full Text] [Related]  

  • 47. . . . from the 3rd International Workshop on salvage therapy for HIV infection.
    Res Initiat Treat Action; 2000 Jun; 6(2):25-8. PubMed ID: 11707875
    [No Abstract]   [Full Text] [Related]  

  • 48. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS.
    Sambamoorthi U; Moynihan PJ; McSpiritt E; Crystal S
    Am J Public Health; 2001 Sep; 91(9):1474-81. PubMed ID: 11527784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of combination antiretroviral therapy.
    Collier AC
    Adv Exp Med Biol; 1996; 394():355-72. PubMed ID: 8815701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors.
    Sapre NS; Gupta S; Pancholi N; Sapre N
    J Mol Model; 2008 Nov; 14(11):1009-21. PubMed ID: 18642033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Production of resistant HIV mutants during antiretroviral therapy.
    Ribeiro RM; Bonhoeffer S
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7681-6. PubMed ID: 10884399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The picture of future therapy.
    Gazzard B
    Int J Clin Pract Suppl; 1999 Jun; 103():45-8. PubMed ID: 10622045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.